Regulation of follow-on biologics

New England Journal of Medicine

Volumn 357, Issue 9, 2007, Pages 841-843

  Frank, Richard G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FLUOXETINE; HUMAN GROWTH HORMONE; HUMAN INSULIN; IMIGLUCERASE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HEPATITIS B VACCINE;

ANEMIA; CANCER; CERVICAL DYSTONIA; DIABETES MELLITUS; DIPHTHERIA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DYSTONIA; GAUCHER DISEASE; HEMOPHILIA; HEPATITIS B; HUMAN; INFECTION; NEUTROPENIA; PERTUSSIS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SHORT SURVEY; TETANUS;

EID: 34548363291     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp078095     Document Type: Article

References (5)

1. IMS Health. IMS reports U.S. prescription sales jump 8.3 percent in 2006, to $274.9 billion. (Accessed August 9, 2007, at www.imshealth.com/ims/ portal/front/articleC/0,2777,6599_3665_80415465,00.html.)
2. Office of Technology Assessment. Pharmaceutical R&D: costs, risks, and rewards. Washington, DC: Government Printing Office, February 1993.
3. Carey S. Lilly reports 22% decline in net as generics hurt sales of Prozac. Wall Street Journal. April 30, 2002.
4. Reiffen D, Ward MR. Generic drug industry dynamics. Rev Econ Stat 2005;87:37-49.
5. Pharmaceutical Research and Manufacturers of America. Pharmaceutical industry profile 2007. Washington DC: PhRMA, 2007.